Lexicon Pharmaceuticals LXRX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Lexicon Pharmaceuticals (LXRX) reported unrealized gains (losses) on available-for-sale securities of -$160K in Q1 2026.
- How has Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities decreased by 70.2% year-over-year, from -$94K to -$160K.
- What is the long-term trend for Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Lexicon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities has grown at a 374.3% compound annual growth rate (CAGR), from -$4K to -$90K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- The change in the fair value of investment securities held by the company that has not yet been realized through a sale. This reflects market-driven fluctuations in the value of the company's treasury or investment portfolio.